Inhibitory impact of A1 and A2 cow’s milk on human peripheral blood mononuclear cells identifies TOM1 as a candidate anti-inflammatory mediator - Takeaways - MDSpire

Inhibitory impact of A1 and A2 cow’s milk on human peripheral blood mononuclear cells identifies TOM1 as a candidate anti-inflammatory mediator

  • By

  • Lili M. Flad

  • Tanja Weißer

  • Jonas Liedl

  • Felix Gard

  • Agnese Petrera

  • Christine von Toerne

  • Stefanie M. Hauck

  • Cornelia A. Deeg

  • Kristina J. H. Kleinwort

  • June 10, 2026

  • 0 min

Share

  • 1

    A1 and A2 cow's milk have been shown to inhibit the proliferation of human peripheral blood mononuclear cells (PBMC) stimulated by Concanavalin A.

  • 2

    High molecular weight fractions (HWF) of both A1 and A2 milk were identified as the inhibitory components affecting PBMC proliferation.

  • 3

    Target of Myb protein 1 (TOM1) was significantly increased in PBMC supernatants after co-incubation with HWFs from both milk types.

  • 4

    TOM1 demonstrated an inhibitory effect on stimulated human PBMC, suggesting its role as an anti-inflammatory mediator.

  • 5

    The study highlights the potential of milk components, particularly TOM1, in modulating immune responses through Interleukin-1β signaling.

Original Source(s)

Inhibitory impact of A1 and A2 cow’s milk on human peripheral blood mononuclear cells identifies TOM1 as a candidate anti-inflammatory mediator

  • by Lili M. Flad, Tanja Weißer, Jonas Liedl, Felix Gard, Agnese Petrera, Christine von Toerne, Stefanie M. Hauck, Cornelia A. Deeg, Kristina J. H. Kleinwort

  • June 10, 2026

Related Content

OI Therapy Raised BMD, Not Fracture Benefit

Teriparatide followed by zoledronic acid increased bone mineral density but did not reduce fracture risk compared with standard care in adults with osteogenesis imperfecta.

Tumor safety of biologic agents and targeted therapies in immune-mediated inflammatory arthritides

Editorial: Autoantibodies in cancer: diagnostic, prognostic, and therapeutic potential